Palopegteriparatide: complete guide

Palopegteriparatide is a slow-release PTH(1-34) prodrug approved by FDA as Yorvipath in 2024. This guide covers its structure, mechanism, labeled use, trials and warnings.

Complete guide5 min read

Key takeaway

FDA approved palopegteriparatide as Yorvipath on August 9, 2024, for hypoparathyroidism in adults. Its average molecular weight is about 47.4 kDa, mostly from the carrier. In the pivotal trial, 68.9% of Yorvipath patients met the label’s efficacy endpoint at week 26, versus 4.8% on placebo.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Yorvipath on August 9, 2024.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited3 in this article · 3 across 1 article on Palopegteriparatide
Related productsIncretin analogs

Palopegteriparatide is a prodrug of PTH(1-34), the active front part of human parathyroid hormone. The peptide is tied to a polyethylene glycol carrier through a linker that releases it slowly. This guide covers its structure, mechanism, FDA-labeled use, pivotal trial and label warnings. Sources were checked on November 17, 2026.

Quick answer: Palopegteriparatide is a prescription parathyroid hormone analog sold as Yorvipath by Ascendis Pharma. It replaces missing parathyroid hormone in adults with hypoparathyroidism. It has no boxed warning. Label warnings include serious high or low blood calcium, a potential risk of osteosarcoma and drops in blood pressure on standing.

Vitrapep does not sell palopegteriparatide; this page is a reference summary of published research and regulatory information.

What is palopegteriparatide?

The Yorvipath label calls it “a parathyroid hormone analog (PTH(1-34)).” It adds that PTH(1-34) “is identical to the 34 N-terminal amino acids (the biologically active region)” of human parathyroid hormone (Yorvipath label, 2026). Full-length parathyroid hormone has 84 amino acids, so this is its first 34 (Natpara label, 2022).

The drug is built in three parts. The peptide is the active part. A proprietary TransCon linker holds it for a time and then lets it go. The carrier is “a branched 40 kDa (2×20 kDa) methoxypolyethylene glycol (mPEG) moiety.” The label gives an average molecular weight of about 47.4 kDa. PubChem has no compound record for palopegteriparatide, so no single molecular formula is shown here.

It counts as a peptide medicine because the active part is a 34-amino-acid chain. The same chain is sold on its own as teriparatide. Our peptide primer covers the basics. Drugs@FDA lists the original approval of Yorvipath (NDA 216490) on August 9, 2024, to Ascendis Pharma Bone (Drugs@FDA).

Table 1

Palopegteriparatide: key facts

Fact Detail
Structure type Prodrug: PTH(1-34) peptide joined by a TransCon linker to a branched 40 kDa mPEG carrier
Class Parathyroid hormone analog
Molecular formula Not listed (PubChem has no compound record for this conjugate)
Molecular weight About 47.4 kDa (average, per label)
First FDA approval August 9, 2024 (Yorvipath, NDA 216490)
Brand names (US) Yorvipath (Ascendis Pharma)

How does palopegteriparatide work?

In hypoparathyroidism, the parathyroid glands make too little hormone. Blood calcium falls. Standard care has relied on calcium and active vitamin D.

The label explains that “at physiological conditions, palopegteriparatide releases PTH(1-34) to maintain a continuous systemic exposure.” Once freed, PTH(1-34) acts on the PTH1 receptor, the main receptor for natural parathyroid hormone. In plain terms, the carrier slowly lets out the active peptide, aiming for steady hormone levels rather than peaks (Yorvipath label, 2026). Our guide to peptide half-life explains why carriers like this are used.

What is palopegteriparatide approved for?

The Yorvipath label states: “YORVIPATH is indicated for the treatment of hypoparathyroidism in adults.”

It lists a limit of use. The label states that Yorvipath “was not studied for acute post-surgical hypoparathyroidism.” FDA’s announcement says the application received orphan drug designation and priority review (FDA, 2024).

What did the key trials show?

PaTHway, 26 weeks. The pivotal human trial was a randomized, double-blind, placebo-controlled phase 3 study in 82 adults with hypoparathyroidism. Sixty-one received Yorvipath and 21 received placebo. The label’s endpoint was a composite at week 26. Patients needed normal albumin-corrected calcium, independence from active vitamin D and therapeutic calcium, and no recent increase in study drug.

By the label’s analysis, 68.9% (42 of 61) of Yorvipath patients met the endpoint, compared with 4.8% (1 of 21) on placebo. The difference was 64.2 percentage points (Yorvipath label, 2026). The published report used the trial’s own composite definition and reported 79% versus 5% (P < 0.0001). All hypoparathyroidism symptom scores also improved compared with placebo (Khan et al., 2023). The registry record is NCT04701203.

PaTHway, 52 weeks. After the blinded period, patients could continue in an open-label extension. At week 52, 81% (63 of 78) met the multicomponent endpoint. In that group, 95% were independent of conventional therapy (Clarke et al., 2025). This extension had no placebo group.

PaTHway, 3.5 years. A report published online in October 2026 followed patients through week 182. Among 73 who completed that visit, 89% had normal calcium, and most no longer needed calcium or active vitamin D (Khan et al., 2026).

What side effects does the label list?

The Yorvipath label has no boxed warning. Reactions in 5% or more of trial patients, Yorvipath versus placebo:

  • Local site reactions: 39% versus 5%
  • Vasodilatory signs and symptoms, such as lower blood pressure and dizziness: 28% versus 0%
  • Headache: 21% versus 10%
  • Diarrhea: 10% versus 5%
  • Back pain and hypercalcemia: 8% each versus 0%
  • Oropharyngeal (throat) pain: 7% versus 0%

The label’s warnings and precautions cover hypersensitivity reactions, serious hypercalcemia and serious hypocalcemia. They also cover a potential risk of osteosarcoma, a bone cancer, and orthostatic hypotension. A further warning concerns digoxin toxicity when used with digitalis drugs. Another covers unintended calcium changes linked to how the product is used (Yorvipath label, 2026).

What is palopegteriparatide’s regulatory status, and how is it used in research?

Palopegteriparatide is a prescription drug in the United States. Drugs@FDA lists Yorvipath with a prescription marketing status. The current label on DailyMed, from Ascendis Pharma, Endocrinology, Inc., was revised in October 2026.

FDA’s Drug Trials Snapshot for Yorvipath describes the same single trial of 82 adults as the basis for approval (FDA Drug Trials Snapshot). The research summarized here is clinical, in human patients. We found no documented role as a laboratory reagent in the sources we checked.

Frequently asked questions about palopegteriparatide

Is palopegteriparatide a peptide?

Its active part is. It is a 34-amino-acid peptide, PTH(1-34), joined to a polyethylene glycol carrier through a releasable linker.

When was palopegteriparatide approved?

Drugs@FDA lists the original approval of Yorvipath on August 9, 2024.

How is it different from teriparatide?

Teriparatide (Forteo) is PTH(1-34) on its own (Forteo label, 2026). Palopegteriparatide carries the same peptide on a slow-release carrier and is labeled for hypoparathyroidism.

How is it different from Natpara?

Natpara contained full-length parathyroid hormone, all 84 amino acids (Natpara label, 2022). Yorvipath releases only the first 34. See our parathyroid hormone guide for Natpara’s history.

Does palopegteriparatide have a boxed warning?

No. Its warnings include serious high or low calcium and a potential risk of osteosarcoma.

What to know now

  • Structure: PTH(1-34) on a TransCon linker and a branched 40 kDa mPEG carrier; about 47.4 kDa.
  • Approval: Yorvipath, August 9, 2024; prescription only; orphan designation and priority review.
  • Label use: hypoparathyroidism in adults; not studied in acute post-surgical cases.
  • Evidence: 68.9% versus 4.8% met the label endpoint at week 26.
  • Safety: no boxed warning; local site reactions, vasodilatory symptoms and headache were most common.

What we’re watching

Further Yorvipath label revisions on DailyMed, last revised in October 2026. The final, print version of the 3.5-year PaTHway report, now online ahead of print. Related guides: parathyroid hormone, teriparatide and etelcalcetide.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Ascendis Pharma 2026, YORVIPATH (palopegteriparatide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 216490 (YORVIPATH) . Retrieved November 17, Drugs@FDA: NDA 216490 (YORVIPATH); U.S. Food and Drug Administration 2024, FDA approves new drug for hypoparathyroidism, a rare disorder; U.S. Food and Drug Administration. Drug Trials Snapshots: YORVIPATH . Retrieved November 17, Drug Trials Snapshots: YORVIPATH; Khan 2023, Journal of Bone and Mineral Research, 38; Clarke 2025, The Journal of Clinical Endocrinology & Metabolism, 110; Ascendis Pharma Bone Diseases A/S 2021; Khan 2026, The Journal of Clinical Endocrinology & Metabolism; Shire-NPS Pharmaceuticals 2022, NATPARA (parathyroid hormone) prescribing information; Eli Lilly and Company 2026, FORTEO (teriparatide) prescribing information. All 10 citations

Back to the research library

References

  1. Ascendis Pharma, Endocrinology, Inc. (2026). YORVIPATH (palopegteriparatide) prescribing information (revised 10/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1fa23fd-c434-443e-9a17-5750578c8602
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 216490 (YORVIPATH). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216490
  3. U.S. Food and Drug Administration. (2024, August 9). FDA approves new drug for hypoparathyroidism, a rare disorder. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-hypoparathyroidism-rare-disorder
  4. U.S. Food and Drug Administration. Drug Trials Snapshots: YORVIPATH. Retrieved November 17, 2026, from https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-yorvipath
  5. Khan, A. A., et al. (2023). Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. Journal of Bone and Mineral Research, 38(1), 14-25. https://doi.org/10.1002/jbmr.4726
  6. Clarke, B. L., et al. (2025). Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial. The Journal of Clinical Endocrinology & Metabolism, 110(4), 951-960. https://doi.org/10.1210/clinem/dgae693
  7. Ascendis Pharma Bone Diseases A/S. (2021). A trial investigating the safety, tolerability and efficacy of TransCon PTH administered daily in adults with hypoparathyroidism (PaTHway) (ClinicalTrials.gov ID NCT04701203). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04701203
  8. Khan, A. A., et al. (2026). Palopegteriparatide in adults with hypoparathyroidism: 3.5-year results from the phase 3 PaTHway trial. The Journal of Clinical Endocrinology & Metabolism. Advance online publication. https://doi.org/10.1210/clinem/dgag440
  9. Shire-NPS Pharmaceuticals, Inc. (2022). NATPARA (parathyroid hormone) prescribing information (revised 04/2022). Drugs@FDA, U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125511s028lbl.pdf
  10. Eli Lilly and Company. (2026). FORTEO (teriparatide) prescribing information (revised 8/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0